Somatropin vs Ibutamoren

Head-to-head comparison of Somatropin (Recombinant human growth hormone (rhGH)) and Ibutamoren (Ibutamoren mesylate (MK-677)) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertySomatropinIbutamoren
CategoryGrowth HormoneGrowth Hormone
Full NameRecombinant human growth hormone (rhGH)Ibutamoren mesylate (MK-677)
Molecular Weight22125 DaN/A
Half-Life2-4 hoursabout 24 hours
Amino Acids191N/A
Typical Dose0.004-0.03 mg/kg/day10-25 mg/day
RouteSubcutaneousOral
Purity≥98%≥98%
Studies Count2000180
Research StatusClinical/ApprovedClinical

Somatropin Benefits

  • linear growth support
  • lean mass preservation
  • bone mineral accrual
  • IGF-1 elevation

Ibutamoren Benefits

  • raises GH/IGF-1
  • increases appetite
  • supports lean mass retention
  • oral non-peptide secretagogue

Somatropin Dosing

daily subcutaneous dosing|titrate to IGF-1 and response|weight-based replacement protocols

Ibutamoren Dosing

10-25 mg orally once daily|take consistently at the same time each day|monitor fasting glucose and edema in longer studies

Somatropin Side Effects

  • edema
  • arthralgia
  • insulin resistance

Ibutamoren Side Effects

  • increased appetite
  • water retention/edema
  • somnolence or lethargy

Research Overview

Somatropin

Somatropin is the best-studied growth hormone peptide, with decades of clinical use in pediatric and adult GH deficiency. Trials consistently show increases in IGF-1 and growth velocity, with adverse effects mainly reflecting excessive GH exposure.

Ibutamoren

Clinical studies show oral ibutamoren reliably elevates GH and IGF-1 over 24 hours with once-daily dosing. Body composition and appetite effects vary by population, and development has been limited by metabolic side effects.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Ibutamoren stacks with:

Resistance trainingHigh-protein diet
gh-axisanabolicigf-1clinicalghrelin-receptor-agonistgh-secretagogueoral